<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Tim</forename><forename type="middle">Bastian</forename><surname>Braemswig</surname></persName>
							<email>tim-bastian.braemswig@charite.de</email>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">Berlin Institute of Health (BIH)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christoph</forename><forename type="middle">C</forename><surname>Eschenfelder</surname></persName>
							<affiliation key="aff2">
								<orgName type="department">Ingelheim am Rhein</orgName>
								<orgName type="institution" key="instit1">Boehringer Ingelheim Pharma GmbH &amp; Co. KG</orgName>
								<orgName type="institution" key="instit2">Medical Affairs Germany</orgName>
								<address>
									<addrLine>Binger Straße 173</addrLine>
									<postCode>55216</postCode>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christian</forename><forename type="middle">H</forename><surname>Nolte</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin Berlin</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">Berlin Institute of Health (BIH)</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Emergency LP in a patient receiving dabigatran after antagonization with idarucizumab</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">747CDA0AC537629B7295821FA1EEDB61</idno>
					<idno type="DOI">10.1016/j.ajem.2016.10.068</idno>
					<note type="submission">Received 11 October 2016 Accepted 28 October 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Idarucizumab is an antibody fragment which is used to reverse the anticoagulant effects of dabigatran.</s><s>We report on the first successful use of idarucizumab before performing an emergency lumbar puncture in a patient on effective anticoagulation with dabigatran thought to have infective cerebral disease (such as temporal encephalitis).</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>An 85-year-old male patient was admitted to our emergency department (ED) with fever (38.6 °C/101.5 °F) and new onset of aphasia at night in late February 2016.</s><s>The patient was on dabigatran 110 mg BID because of non valvular atrial fibrillation (NVAF).</s><s>In addition, the patient had also been diagnosed with hypertension, hyperlipidemia and chronic renal insufficiency.</s><s>The patient was last seen without aphasia the day before admission.</s><s>Time of last dabigatran intake was unknown at the time of presentation in our ED.</s><s>Neurological status on admission revealed a severe aphasia (NIHSS [National Institutes of Health Stroke Scale] = 4).</s><s>The Glasgow Coma Scale (GCS) was 13 (patient was confused, disoriented).</s></p><p><s>Magnetic resonance imaging (MRI) was not available at night.</s><s>The emergency computer tomography scan showed no signs of acute cerebral ischemia or hemorrhage.</s><s>The thrombin time (TT) was 55.8 s (normal b13.0 s) and the activated partial thromboplastin time (aPTT) was 45.3 s (normal range: 26.0-40.0</s><s>s).</s><s>The creatinine clearance was 52 ml/min, the C-reactive protein (CRP) was 18.5 mg/l (normal b 5.0 mg/l) and the leukocyte count was 7.55/nl (normal range: 3.90-10.50/nl).</s></p><p><s>Differential diagnoses included stroke with unknown onset with accompanying infective disease and infective cerebral disease such as temporal encephalitis (new aphasia, fever and elevated CRP).</s><s>We decided to perform an emergency lumbar puncture to narrow down differential diagnosis.</s><s>Therefore, we first injected the patient with 5 g idarucizumab.</s><s>Thrombin time (TT) and the activated partial thromboplastin time (aPTT) both rapidly normalized.</s><s>TT was 10.6 s (normal b13.0 s) and aPTT was 32.7 s (normal range: 26.0-40.0</s><s>s) after idarucizumab application.</s><s>Lumbar puncture was performed without difficulties.</s><s>We did not notice any bleeding during or following the procedure.</s><s>Cerebrospinal fluid (CSF) showed very mild pleocytosis (number of cells: 5/μl; normal range: 0-4/μl).</s><s>PCR did not show herpes simplex, varicella zoster or Epstein-Barr virus within CSF.</s></p><p><s>On the next day, magnetic resonance imaging revealed a subacute middle cerebral artery infarction.</s><s>Duplex sonography revealed a highgrade left-sided proximal internal carotid artery stenosis (90% according to NASCET criteria).</s><s>Additionally, an acute laryngitis was diagnosed.</s><s>The patient was given antibiotics because of the laryngitis.</s><s>Carotid endarterectomy was performed because of the high grade stenosis.</s><s>Following surgery, we recommended to continue medical therapy with a NOAC because of NVAF.</s></p><p><s>Idarucizumab is a humanized monoclonal antibody fragment (Fab) indicated in patients treated with dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding <ref type="bibr" target="#b0">[1]</ref><ref type="bibr" target="#b1">[2]</ref><ref type="bibr" target="#b2">[3]</ref>.</s><s>For the first time, we report on a patient receiving dabigatran 110 mg BID in whom idarucizumab was successfully used before performing an emergency lumbar puncture.</s><s>This adds important information to very recent case reports describing the use of idarucizumab before intravenous thrombolysis with recombinant tissue-type plasminogen activator in stroke patients receiving dabigatran <ref type="bibr" target="#b3">[4,</ref><ref type="bibr" target="#b4">5]</ref>.</s></p><p><s>In our report, emergency lumbar puncture was indicated because of possible infective cerebral disease (aphasia, fever and elevated CRP).</s><s>In ED more thorough history taking was not possible due to severe aphasia and lack of relatives to report further details on the onset or dynamics of the disease.</s><s>Therefore, we could not determine the time of intake of the last dabigatran dose.</s><s>The results of the coagulation tests (aPTT and TT both increased) suggested effective dabigatran concentration <ref type="bibr" target="#b1">[2]</ref>.</s><s>Application of 5 g idarucizumab resulted in prompt normalization of coagulation tests, indicating a successful antagonization of the anticoagulant effects of dabigatran.</s><s>Lumbar puncture, which requires normal hemostasis, was performed without difficulties or complications in the ED helping to narrow down differential diagnosis.</s></p><p><s>Alternative strategies for this emergency setting included: (1) Performing MRI/MR-Angiography (MRA)/Computed tomography Angiography (CTA), (2) empirical treatment with aciclovir.</s><s>Because MRI was not available at night we discussed both performing CTA and empirical treatment with aciclovir.</s><s>In both cases, however, we opted for lumbar puncture because renal insufficiency might have worsened following CTA or aciclovir application.</s><s>The differential diagnosis of encephalitis was made unlikely in a timely manner.</s></p><p><s>We demonstrated that idarucizumab can be successfully used before performing an emergency lumbar puncture in a patient on effective anticoagulation with dabigatran.</s></p></div>		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" />
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure</head><p><s>Dr. C.C. Eschenfelder is an employee of Boehringer Ingelheim.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">A specific antidote for dabigatran: functional and structural characterization</title>
		<author>
			<persName><forename type="first">F</forename><surname>Schiele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Ryn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Newsome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sepulveda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Nar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="3554" to="3562" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Idarucizumab the antidote for reversal of dabigatran</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Eikelboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Quinlan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Ryn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">I</forename><surname>Weitz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="2412" to="2422" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Idarucizumab for dabigatran reversal</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">V</forename><surname>Pollack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Reilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Eikelboom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Glund</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Verhamme</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bernstein</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1502000</idno>
		<ptr target="http://dx.doi.org/10.1056/NEJMoa1502000" />
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">373</biblScope>
			<biblScope unit="page" from="511" to="520" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab</title>
		<author>
			<persName><forename type="first">J</forename><surname>Berrouschot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Stoll</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Hogh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Eschenfelder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stroke</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="1936" to="1938" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab-a case report</title>
		<author>
			<persName><forename type="first">N</forename><surname>Schäfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Wüllner</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jstrokecerebrovasdis.2016.05.006</idno>
		<ptr target="http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2016.05.006.662.e4" />
	</analytic>
	<monogr>
		<title level="j">J Stroke Cerebrovasc Dis</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="e126" to="127" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Braemswig</surname></persName>
		</author>
		<idno>e3-662.e4</idno>
	</analytic>
	<monogr>
		<title level="j">American Journal of Emergency Medicine</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
